Bird & Bird's broad offering has an established track record in acting for clients in proceedings before the General Court (EGC) and the Court of Justice of the European Union (CJEU), often involving data protection issues, market authorisations and ethical considerations. Practice head Marc Martens is highly regarded for his expertise in handling data exclusivity cases, as well as assisting with biobanking and clinical trials work. Jean-Christophe Troussel leads the firm’s IP group, and is a key contact for patent license matters and research and development (R&D) deals. Corporate expert Paul Hermant brings experience in advising on venture capital financings and M&A transactions, and regulatory expert Kevin Munungu is well versed in handling public procurement matters for clients in the life sciences sector. Domien Op De Beeck is a key contact for IP-related mandates.

Covington & Burling LLP stands out for its 'truly unique expertise and experience in the topic of national and multilateral benefit-sharing for pathogens'. The team is well known for its strength in handling EU pharmaceutical regulatory issues and reimbursement procedures. Peter Bogaert is highly regarded for his extensive experience in advising on matters concerning medical devices and biotech issues; he co-heads the practice with Bart Van Vooren, who routinely appears before the CJEU and the EGC in contentious matters involving clinical trials' data.

The team at Crowell & Moring has an excellent track record in representing clients before Belgian and EU courts in contentious work concerning SPCs, patents and market protection issues. Practice head Kristof Roox is a highly regarded patent litigator with extensive regulatory knowledge, with solid experience in advising on pharma marketing work and distribution issues. Matteo Mariano regularly acts for medical device companies in patent enforcement cases, and acts as counsel to SMEs and start-ups in the life sciences industry. Jurgen Figys is well versed in acting for healthcare, pharma, and biotech corporations in data exclusivity and reimbursement cases. Wietse Vanpoucke is a key contact for digital health matters, while Christopher Dumont focuses on trade mark and patent disputes.

Quinz‘s practice stands out for its strong transactional and regulatory capabilities, often advising on transparency regulations, healthcare compliance matters, and competition issues. Olivier Van Obberghen has a solid track record in handling pharma compliance work and supply chain projects; he co-heads the practice with Pieter Wyckmans, who is well versed in advising on market access issues and pricing and reimbursement work. International research collaboration matters form a key pillar of Michiel D’herde's practice, and Marion Lapage fields expertise in R&D outsourcing projects and distribution issues. Amber Cockx often advises on digital health matters, and Pauline Meskens focuses on market access and parallel imports issues.

The 'very hands-on' Catherine Longeval and Peter L’Ecluse co-head Van Bael & Bellis' practice, which is well versed in handling contentious and non-contentious public health and public procurement issues. Longeval is highly regarded for her extensive regulatory expertise, with a core focus on matters concerning medical devices, food and supplements, and biotech products, and L’Ecluse has established strength in assisting with reimbursement matters. Michael Clancy is a key contact for competition issues, and Thibaut D’hulst advises on the full spectrum of IP and data protection issues relating to the life sciences sector. Koen T’Syen assists with clinical trials and market authorisation issues.

A&O Shearman houses a broad practice which is well known for its ability to handle major transactions and complex regulatory work within the life sciences sector. Based in Antwerp, Filip Van Elsen is very experienced in handling digital medicine-related transactions, data protection, and cybersecurity issues. Working out of the Brussels office, Tine Carmeliet has extensive regulatory expertise, often acting as counsel to Belgian biotechs and global medical device and pharma clients on a range of matters. Peter Van Dyck, also based in Brussels, is a key contact for IP litigation, with strength in advising patent revocation proceedings and infringement actions. All named lawyers co-head the practice.

The 'highly dedicated and knowledgeable' team at ALTIUS regularly advises on a broad range of issues in the life sciences sector, with particular strength in handling pricing and reimbursement-related disputes. Christophe Ronse is highly regarded for his expertise in patent litigation, often appearing in local and EU courts in disputes. Philippe de Jong is a name to note for parallel import work, and Kirian Claeyé 'stands out with his extensive knowledge of the industry' and 'encyclopedic knowledge of Belgian life sciences law'. The trio co-head the practice.

Liesbeth Weynants leads the team at HOYNG ROKH MONEGIER, which leverages the strength of the firm's offices in Paris and Amsterdam to support clients on the full spectrum of IP issues concerning the life sciences sector. Weynants is highly regarded for her expertise in advising on a broad range of regulatory issues, including reimbursement and pharmacovigilance matters, as well as assisting with patent enforcement actions and the development of portfolio strategies.  Dividing his time between Brussels and Paris, firm managing partner Benoît Strowel is well versed in handling patent litigation across Europe. Ine Letten brings experience in handling issues concerning unfair business practices and multi-jurisdictional patent litigation. Tim Robrechts assists with a broad range of IP-related issues. Charlotte Behets Wydemans left the firm in February 2024.

Jones Day houses 'an excellent team, with a deep knowledge of the life sciences sector'. The group leverages the strength of the firm's international network to act for a broad client base, including research institutions, in a range of matters, with particular expertise in handling digital health mandates. Practice head Cristiana Spontoni also heads the firm’s wider global healthcare and life sciences group, and is praised as 'an amazing lawyer and a great person to work with on cases'; she has extensive experience in assisting food, cosmetics, and medical device manufacturers with a broad spectrum of regulatory and transactional issues.

Olivier Mignolet and the 'amazing' Annabelle Bruyndonckx co-head Simmons & Simmons' team, which is noted for its strength in public procurement and supply chain issues. Bruyndonckx stands out for her extensive expertise in assisting global pharma and biotech companies with a broad range of regulatory work, and is well known for her strength in advising on digital health and medtech issues. Mignolet is an experienced commercial litigator with a strong focus on assisting with regulatory matters in the healthcare and life sciences sectors. Nele Jonckers and Michael Bulckaert are names to note.

At Stibbe, key areas of strength for the team include advising on market exclusivity matters and regulatory issues concerning hospitals. Practice co-head Ignace Vernimme is very experienced in representing clients in litigation, often before regulatory authorities, and co-head Philippe Campolini is well versed in assisting Belgian and international life science and medical device companies with work. Louis Bidaine has extensive expertise in IP matters, and often advises on patent disputes.

Baker McKenzie CVBA/SCRL's 'amazingly talented, reliable, and professional' team leverages the firm's European network of offices to support clients on a broad range of matters. Roel Meers is well versed in advising medtech and biotech clients on M&A and capital markets transactions, while Fiona Carlin assists pharma clients with the structuring of European distribution networks and supply chain matters. Els Janssens is 'an exceptional expert in regulatory matters', and often acts for industry associations and pharma and medical devices sector entities in mandates. The trio co-head the practice.

Virginie Dor and Bruno Fonteyn co-head the offering at CMS, which is well known for its strength in advising on the full range of public procurement and competition-related work. Fonteyn often assists with matters involving hospitals and medical equipment, while Dor, who also acts as head of the firm's public law group, handles large public procurement cases.

At Deloitte Legal, key areas of instruction for the team include development and license agreements, product distribution issues, and MDR-related matters. The group is equally strong in assisting with investment work in the life sciences space. Ghent-based practice head Matthias Vierstraete is a key contact for trade mark, patent, and data protection law. In the Brussels office, Christoph Michiels has longstanding experience in assisting medtech and biotech start-up clients with commercial and IP-related work. Jean-Christophe Top left the firm in January 2024.

The 'responsive and pragmatic' team at DLA Piper leverages the firm's international network of offices to act for global pharma companies in a range of matters. Marco de Morpurgo divides his time between the Rome and Brussels offices, and is well versed in assisting with market access issues, advertising matters and product classification cases; he co-heads the practice with Joost Haans. Jean-Christophe Top joined the team in January 2024.

King & Spalding LLP's team stands out for handling a myriad of issues relating to clinical trials and supply chain matters. Practice head Geneviève Michaux brings expertise in assisting medical device companies, pharmaceutical entities and companies in the cosmetics space with EU regulatory matters. Georgios Symeonidis' workload includes assisting with market authorisations, product classifications and patient use programs.

The team at Loyens & Loeff regularly advises on investment issues and M&A transactions in the sector. Stéphanie De Smedt heads the practice, and is well known for her expertise in contractual matters and data protection law, with established experienced in handling work involving the Clinical Trials Regulation and GDPR. Valentijn De Boe, who leads the firm’s public law group, assists pharma companies and investors with public-private partnerships. Employment law specialist Valentijn De Boe is well-placed to advise major healthcare and life sciences corporations on the employment aspects of transactions and reorganisations.

NautaDutilh is well versed in advising on IP matters in the healthcare and life sciences space, with a particular focus on trade mark issues. Practice co-head Florence Verhoestraete has a solid track record in handling unfair competition matters, licensing work, and patent disputes. Co-head Philippe Remels draws on his extensive expertise in corporate and M&A to assist with private financing rounds in the life sciences sector. Axel Maeterlinck joined the team in July 2024.

Osborne Clarke's team's 'healthcare regulatory expertise is top-notch'. Practice head Hadrien Chef draws on his corporate expertise to assist with corporate finance matters and public and private M&A in the sector. Vladimir Murovec is 'a skilled regulatory and compliance lawyer with solid expertise in cross-border pharmaceutical regulatory matters'.

Simont Braun's broad practice is active across a wide spectrum of matters, including marketing, IP, M&A and corporate issues. Practice co-head Eric De Gryse has extensive IP litigation experience, and is active on pharma and food product patent and trade mark disputes. Co-head and trade mark specialist Emmanuel Cornu acts for luxury cosmetics companies in mandates. Axel Maeterlinck left the firm in July 2024.

Taylor Wessing‘s practice is well versed in acting for major pharma and medical device companies, and has a strong track record in appearing in patent infringement proceedings and revocation actions. Practice head Christian Dekoninck is very experienced in handling patent litigation for clients in the pharma industry, and Marie Keup is very experienced in handling R&D and license agreements. Patricia Cappuyns left the firm in April 2024.